Search Within

Genitourinary Oncology Service

  1. "Value in Health"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (2)
Groups
  1. Department of Medicine (12)
  2. Solid Tumor Oncology Division (12)
  3. Epidemiology and Biostatistics (2)
  4. Health Outcomes Research Group (2)
  5. Population Sciences Research Program (2)
People
  1. Robert Motzer (10)
  2. Aaron Mitchell (2)
Years
  1. 2024 (2)
  2. 2019 (1)
  3. 2018 (1)
  4. 2017 (1)
  5. 2015 (1)
  6. 2011 (1)

More Years

Publications
  1. Value in Health (12)
Publishers
  1. Elsevier Science, Inc. (12)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The effect of biosimilar entry on biologic drug prices in Medicare part B
    Meeting Abstract

    Winn, A.; Abdelaziz, A.; Dusetzina, S. B.; Mitchell, A. P.
    Value in Health (2024)

    Fulltext@MSK | Save
  • Assessment of supporting evidence and postmarketing requirements for therapeutic indications with Real-Time Oncology Drug Review, 2018-2023
    Meeting Abstract

    Mooghali, M.; Mohammad, A.; Wallach, J. D.; Mitchell, A. P.; Ross, J. S.; Ramachandran, R.
    Value in Health (2024)

    Fulltext@MSK | Save
  • Quality adjusted time without symptoms of disease progression or toxicity (Q-TWIST) of nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) among untreated advanced renal cell carcinoma (ARCC) patients (patients) with intermediate or poor prognostic risk
    Meeting Abstract

    Shah, R.; Botteman, M.; Kwon, Y.; Gooden, K. M.; Cella, D.; Motzer, R.
    Value in Health (2019)

    Fulltext@MSK | Save
  • Important group differences on the Functional Assessment of Cancer Therapy–Kidney Symptom Index Disease-Related Symptoms in patients with metastatic renal cell carcinoma
    Journal Article

    Cella, D.; Motzer, R. J.; Rini, B. I.; Cappelleri, J. C.; Ramaswamy, K.; Hariharan, S.; Arondekar, B.; Bushmakin, A. G.
    Value in Health (2018)

    Fulltext@MSK | Save
  • Important group differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index disease-related symptoms (FKSI-DRS) in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Cella, D.; Motzer, R.; Rini, B. I.; Cappelleri, J. C.; Ramaswamy, K.; Arondekar, B.; Bushmakin, A. G.
    Value in Health (2017)

    Fulltext@MSK | Save
  • Cost comparison of first line metastatic renal cell carcinoma treatments using a retrospective claims dataset
    Meeting Abstract

    Margolis, J.; Princic, N.; Doan, J.; Lenhart, G.; Motzer, R.
    Value in Health (2015)

    Fulltext@MSK | Save
  • Using a Weibull parametric model for failure-time data to assess progression-free survival as a surrogate endpoint for overall survival in a trial of patients with metastatic renal cell carcinoma
    Meeting Abstract

    Negrier, S.; Bushmakin, A. G.; Cappelleri, J. C.; Charbonneau, C.; Sandin, R.; Michaelson, M. D.; Figlin, R. A.; Motzer, R. J.
    Value in Health (2011)

    Fulltext@MSK | Save
  • Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa, as first-line therapy in patients with metastatic renal cell carcinoma (MRCC)
    Meeting Abstract

    Cella, D.; Michaelson, M. D.; Bushmakin, A. G.; Cappelleri, J. C.; Charbonneau, C.; Kim, S. T.; Li, J. Z.; Motzer, R. J.
    Value in Health (2009)

    Fulltext@MSK | Save
  • Using the rasch model to validate and enhance the interpretation of the functional assessment of cancer therapy-kidney symptom index - Disease-related symptoms scale
    Journal Article

    Luo, X.; Cappelleri, J. C.; Cella, D.; Li, J. Z.; Charbonneau, C.; Kim, S. T.; Chen, I.; Motzer, R. J.
    Value in Health (2009)

    Fulltext@MSK | Save
  • An updated geographic subpopulation analysis of health-related quality of life (HRQOL) in patients with metastatic renal cell carcinoma (MRCC) enrolled in a phase III trial of sunitinib versus interferon-alfa
    Meeting Abstract

    Cella, D.; Bushmakin, A. G.; Cappelleri, J. C.; Kim, S. T.; Motzer, R. J.; Charbonneau, C.
    Value in Health (2008)

    Fulltext@MSK | Save